Nkarta, Inc. Common Stock
NKTX Real Time Price USDRecent trades of NKTX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by NKTX's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Genetically modified natural killer cells for cd70-directed cancer immunotherapy Jun. 18, 2024
-
Patent Title: Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy Jun. 21, 2022
-
Patent Title: Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy Feb. 22, 2022
-
Patent Title: Cancer immunotherapy using cd19-directed chimeric antigen receptors Oct. 26, 2021
-
Patent Title: Immune cells engineered to express cd19-directed chimeric antigen receptors and uses thereof in immunotherapy Oct. 12, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of NKTX in WallStreetBets Daily Discussion
Recent insights relating to NKTX
Recent picks made for NKTX stock on CNBC
ETFs with the largest estimated holdings in NKTX
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NKTX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.